News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,059 Results
Type
Article (14522)
Company Profile (37)
Press Release (265500)
Section
Business (80270)
Career Advice (1316)
Deals (15944)
Drug Delivery (29)
Drug Development (48262)
Employer Resources (54)
FDA (7672)
Job Trends (6459)
News (150611)
Policy (12590)
Tag
Academia (993)
Africa (373)
Allergies (30)
Alliances (14931)
Alzheimer's disease (570)
Antibody-drug conjugate (ADC) (37)
Approvals (7642)
Artificial intelligence (37)
Asia (19959)
Australia (3712)
Bankruptcy (111)
Best Places to Work (5420)
Breast cancer (60)
C2C Services and Suppliers (25745)
California (1207)
Canada (528)
Cancer (448)
Career advice (1020)
Cell therapy (85)
China (98)
Clinical research (40062)
Collaboration (103)
Colorado (47)
Compensation (62)
Connecticut (49)
COVID-19 (1158)
Data (370)
Delaware (36)
Diabetes (59)
Diagnostics (2474)
Earnings (48208)
Employer resources (47)
Europe (40784)
Events (44363)
Executive appointments (77)
FDA (7855)
Florida (151)
Funding (101)
Gene therapy (59)
GLP-1 (320)
Government (1625)
Healthcare (8028)
Hotbed/Location (190132)
Illinois (111)
Indiana (88)
Infectious disease (1180)
Inflammatory bowel disease (41)
Interviews (247)
IPO (9497)
Japan (31)
Job creations (1181)
Job search strategy (907)
Kansas (48)
Layoffs (162)
Legal (2004)
Liver cancer (38)
Lung cancer (88)
Manufacturing (53)
Maryland (186)
Massachusetts (866)
Medical device (5703)
Medtech (5703)
Mergers & acquisitions (6474)
Metabolic disorders (163)
Michigan (40)
Minnesota (118)
Neuroscience (680)
New Jersey (396)
New York (388)
NextGen Class of 2024 (2399)
Non-profit (2074)
North Carolina (310)
Northern California (557)
Obesity (94)
Ohio (49)
Opinion (74)
Parkinson's disease (31)
Patents (30)
Pennsylvania (329)
People (12690)
Phase I (9819)
Phase II (16431)
Phase III (17172)
Pipeline (125)
Postmarket research (1366)
Preclinical (3265)
Radiopharmaceuticals (116)
Rare diseases (69)
Real estate (1523)
Regulatory (9446)
Research institute (913)
Resumes & cover letters (255)
South America (540)
Southern California (511)
Startups (1073)
Texas (140)
United States (4883)
Vaccines (243)
Washington State (151)
Weight loss (67)
Date
Last 7 days (472)
Last 30 days (1718)
Last 365 days (20143)
2024 (15074)
2023 (21226)
2022 (25568)
2021 (26883)
2020 (25282)
2019 (20187)
2018 (15167)
2017 (15634)
2016 (13557)
2015 (16116)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
280,059 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
3 Major Product Releases at 3Shape Discover Event
3Shape announces the launch of three exciting solutions at its 3Shape Discover digital dentistry event.
June 7, 2024
·
3 min read
DLL3 Targeted Therapies Clinical Trials Insight
Delta-like ligand 3 (DLL3) has emerged as an exciting target for precision cancer medicine. DLL3 is a protein expressed during fetal development that is involved in regulating cell differentiation.
May 21, 2024
·
2 min read
Drug Development
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced completion of enrollment in its ongoing pivotal Phase 3 Iocyte AMI-3 trial of FDY-5301.
June 11, 2024
·
3 min read
Pharm Country
Ansys Enables 3D Multiphysics Visualization of Next-Generation 3D-IC Designs with NVIDIA Omniverse
Ansys (NASDAQ: ANSS) today announced that it is adopting NVIDIA Omniverse application programming interfaces (APIs) to offer 3D-IC designers valuable insights from Ansys’ physics solver results through real-time visualization.
June 19, 2024
·
3 min read
Drug Development
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.
April 23, 2024
·
8 min read
Press Releases
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
September 17, 2024
·
6 min read
Press Releases
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 1, 2024
·
9 min read
Drug Development
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
June 18, 2024
·
25 min read
Drug Development
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that the TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 trial.
May 29, 2024
·
11 min read
Drug Development
Recruitment milestone reached in Diamyd® Phase 3 trial
Diamyd Medical’s precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients.
April 12, 2024
·
4 min read
1 of 28,006
Next